Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [628]

ESMO 2025: Latest developments in endometrial cancer

Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth

ESMO 2025: Latest developments in endometrial cancer ( Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

ESMO 2025: Prostate highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Prostate highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for...

Dr Scott Tagawa - Weill Cornell Medicine, New York, USA

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC ( Dr Scott Tagawa - Weill Cornell Medicine, New York, USA )

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients...

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher...

Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity ( Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada )

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer...

Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, USA

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors ( Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, USA )

ADT with PORT is a good treatment option for men with unfavourable intermediate...

Dr Mack Roach III - University of California San Francisco, San Francisco, USA

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC ( Dr Mack Roach III - University of California San Francisco, San Francisco, USA )

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related...

Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics ( Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA )

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )

Rusfertide shows promise for polycythemia vera treatment

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Rusfertide shows promise for polycythemia vera treatment ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

More from ecancer